This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

About

ButtonLoadingMOA

About

AboutAlopecia AreataBurden of Alopecia AreataMOAEfficacySafety ProfileOverviewSALT score ≤10SALT score ≤20PGI-CEyebrow and Eyelash ResponsesBefore and After Patient ImagesSafety ProfileSafety ProfileContraindications, Special Warnings and PrecautionsAdverse ReactionsPatient ProfilesGetting Started
Getting StartedDosingLaboratory Parameter MonitoringResourcesResourcesVideos
MaterialsContact us

Click here for ▼LITFULO (ritlecitinib) Prescribing Information

Hypothetical patient profiles

Litfulo is contraindicated in pregnancy and breast-feeding. Litfulo is not recommended in women of childbearing potential not using contraception. Women of reproductive potential have to use effective contraception during treatment and for 1 month following the final dose of Litfulo. The effect of Litfulo on fertility has not been evaluated.1

Emily, Female, Age 15Loading  Zain, Male, Age 37 LoadingMaria, Female, Age 33Loading
"I can find it worrying when I wake up with some shedding on my pillow, I sometimes feel like it may be getting worse."

Adolescent with severe alopecia areata
Medical history and physical examination
  • Occasional patchy hair loss for 6 years
  • Duration of current episode: 1.5 years
  • SALT score 65
  • Some hair loss on eyebrows
Prescription Treatment History
  • Emily has tried a range of topical treatments since her hair loss began
Social History
  • Emily is self-conscious at school due to alopecia areata (AA).
  • She was doing well in football, but her parents said she purposely failed a trial for a more competitive team because she fears losing her wig and being teased.
  • Emily's parents are worried that she will miss out on things she enjoys because of her AA.
Treatment Considerations
Clinical:
  • There are limited licensed treatment options for AA and symptoms have not been controlled on topicals.

Consider the benefits and risks of prescribing Litfulo, taking into consideration the contraindications and warnings for women and girls of childbearing potential.


SALT = severity of alopecia tool. SALT scores range from 0 to 100.
With 0 = no scalp hair loss and 100 = total scalp hair loss.1
Back to topLoading
"I still can't believe what's happening to me, alopecia areata just hit me out of nowhere."

Severe alopecia areata
Medical history and physical examination
  • Struggling with alopecia areata (AA) for 1 year
  • Duration of current episode: 12 months
  • SALT score 75
Prescription Treatment History
  • Zain has tried topical treatments
Social History
  • Zain had a full head of hair throughout his life, so AA was shocking to him
  • Zain feels insecure and has been withdrawing from social and family events
  • Zain is struggling to cope with the sudden onset of hair loss
Treatment Considerations
Clinical:
  • Experiencing severe hair loss due to AA
SALT = severity of alopecia tool. SALT scores range from 0 to 100.
With 0 = no scalp hair loss and 100 = total scalp hair loss.1
Back to topLoading
"It's heartbreaking to see more of my hair fall out each day."

Uncontrolled severe alopecia areata
Medical history and physical examination
  • Struggling with alopecia areata (AA) for 7 years
  • Duration of current episode: 2.5 years
  • SALT score 60
Prescription Treatment History
  • Maria has used topical and oral treatments over the course of her AA
Social History
  • Currently works in retail and is getting increasingly uncomfortable dealing with clients
  • Maria hopes to open her own retail business, but worries that her AA will alter the perceptions of the clients she is dealing with
  • Maria worries about the impact that AA will have on her career
Treatment Considerations
Clinical:
  • Current AA episode has been the longest with unresolved symptoms

Consider the benefits and risks of prescribing Litfulo, taking into consideration the contraindications and warnings for women and girls of childbearing potential.


SALT = severity of alopecia tool. SALT scores range from 0 to 100.
With 0 = no scalp hair loss and 100 = total scalp hair loss.1
Back to topLoading
Explore more

See our efficacy profile including SALT evaluation examples and eyebrow and eyelash responses

Learn about Litfulo's Efficacy
Loading

Screening and monitoring guidance to consider when initiating treatment with Litfulo 

Download the Litfulo Initiation Guide
Loading

Learn about the safety profile of Litfulo, including contraindications and Adverse Reactions 

Read Litfulo's Safety Profile
Loading
References:1. LITFULO (ritlecitinib) Pfizer. Summary of Product Characteristics. 
PP-LGF-GBR-0270. August 2025

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2026 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-13934. January 2026
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-13971. December 2025

YesNo
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-GBR-12070. April 2025​​​​​​​
​​​​​​​
You are now leaving PfizerPro

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

PP-UNP-GBR-12107. April 2025
​​​​​​​